After complete treatment ( week 41 analysis ) , median overall survival ( OS ) was 13.0 , 11.9 , and 13.1 months for the modified Intention-to-Treat ( ITT ) population and 15.1 , 12.5 , and 8.9 months for the per-protocol population , respectively .